All In Biotech

Drug Trial Radar · NCT07499050

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Jan 9, 2027

Study completion Jan 9, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.

Conditions

  • Healthy Volunteers
  • Overweight or Obesity

Interventions

  • RO7795081Drug

    RO7795081 will be administered orally once a day.

  • PlaceboDrug

    Placebo will be administered orally once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, Severity, and Causal Relationship to Treatment of Adverse EventsTime frame: Baseline to Safety Follow-Up (26 weeks)
  2. Incidence of Abnormal Clinical Laboratory Test FindingsTime frame: Baseline to Safety Follow-Up (26 weeks)
  3. Incidence of Abnormal Vital SignsTime frame: Baseline to Safety Follow-Up (26 weeks)
  4. Incidence of Abnormal Electrocardiogram (ECG) ResultsTime frame: Baseline to Safety Follow-Up (26 weeks)
  5. Incidence of Abnormal Psychiatry ParametersTime frame: Baseline to Safety Follow-Up (26 weeks)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nanjing Gulou Hospital

    Nanjing, China

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.